{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:12:06Z","timestamp":1789830726053,"version":"4.0.1"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40265-026-02286-1","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T12:31:10Z","timestamp":1771158670000},"page":"429-442","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["More than Glucose Elimination: Additional Benefits of SGLT2 Inhibitors in Glomerular Diseases"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-2323","authenticated-orcid":false,"given":"Lucia","family":"Del Vecchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Fernandez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Fornoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"2286_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJL Heerspink","year":"2016","unstructured":"Heerspink HJL, Perkins BA, Fitchett DH, Husain M, Cherney DZI. Sodium glucose co-transporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation. 2016;134:752\u201372.","journal-title":"Circulation"},{"issue":"1","key":"2286_CR2","doi-asserted-by":"publisher","first-page":"F178","DOI":"10.1152\/ajprenal.00130.2025","volume":"329","author":"KN Miyata","year":"2025","unstructured":"Miyata KN, Smith DM, Yamashita M, et al. Dapagliflozin, in addition to ramipril, ameliorates kidney disease progression in mice with Alport syndrome. Am J Physiol Renal Physiol. 2025;329(1):F178\u201389.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"10365","key":"2286_CR3","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group","year":"2022","unstructured":"Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801.","journal-title":"Lancet"},{"issue":"7","key":"2286_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","volume":"20","author":"M Packer","year":"2023","unstructured":"Packer M. SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism. Nat Rev Cardiol. 2023;20(7):443\u201362.","journal-title":"Nat Rev Cardiol"},{"key":"2286_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104215","volume":"83","author":"YM Gao","year":"2022","unstructured":"Gao YM, Feng ST, Wen Y, Tang TT, Wang B, Liu BC. Cardiorenal protection of SGLT2 inhibitors: perspectives from metabolic reprogramming. EBioMedicine. 2022;83:104215.","journal-title":"EBioMedicine"},{"issue":"8","key":"2286_CR6","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/s41440-024-01723-6","volume":"47","author":"P Ahwin","year":"2024","unstructured":"Ahwin P, Martinez D. The relationship between SGLT2 and systemic blood pressure regulation. Hypertens Res. 2024;47(8):2094\u2013103.","journal-title":"Hypertens Res"},{"issue":"13","key":"2286_CR7","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","volume":"292","author":"XX Wang","year":"2017","unstructured":"Wang XX, Levi J, Luo Y, et al. SGLT2 protein expression is increased in human diabetic nephropathy. J Biol Chem. 2017;292(13):5335\u201348.","journal-title":"J Biol Chem"},{"issue":"9","key":"2286_CR8","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1517\/14728222.2016.1168808","volume":"20","author":"P Song","year":"2016","unstructured":"Song P, Onishi A, Koepsell H, Vallon V. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets. 2016;20(9):1109\u201325.","journal-title":"Expert Opin Ther Targets"},{"key":"2286_CR9","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1152\/ajprenal.00518.2013","volume":"306","author":"T Rieg","year":"2014","unstructured":"Rieg T, Masuda T, Gerasimova M, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306:F188\u201393.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"2286_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/ckj\/sfx133","volume":"11","author":"B Afsar","year":"2018","unstructured":"Afsar B, Afsar RE, Dagel T, et al. Capillary rarefaction from the kidney point of view. Clin Kidney J. 2018;11(3):295\u2013301.","journal-title":"Clin Kidney J"},{"issue":"3","key":"2286_CR11","doi-asserted-by":"publisher","first-page":"F412","DOI":"10.1152\/ajprenal.00445.2017","volume":"314","author":"H Rajasekeran","year":"2018","unstructured":"Rajasekeran H, Reich HN, Hladunewich MA, et al. Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study. Am J Physiol Renal Physiol. 2018;314(3):F412\u201322.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"11","key":"2286_CR12","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(21)00242-4","volume":"9","author":"HJL Heerspink","year":"2021","unstructured":"Heerspink HJL, Jongs N, Chertow GM, DAPA-CKD Trial Committees and Investigators, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(11):743\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2286_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","volume":"12","author":"EMPA-KIDNEY Collaborative Group","year":"2024","unstructured":"EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12(1):51\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"2286_CR14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","volume":"8","author":"DZI Cherney","year":"2020","unstructured":"Cherney DZI, Dekkers CCJ, Barbour SJ, et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol. 2020;8(7):582\u201393.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2286_CR15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0272-6386(96)90512-0","volume":"27","author":"C Burton","year":"1996","unstructured":"Burton C, Harris KP. The role of proteinuria in the progression of chronic renal failure. Am J Kidney Dis. 1996;27(6):765\u201375.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2286_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12020297","volume":"12","author":"L Della Guardia","year":"2023","unstructured":"Della Guardia L, Codella R. Exercise restores hypothalamic health in obesity by reshaping the inflammatory network. Antioxidants. 2023;12(2):297.","journal-title":"Antioxidants"},{"issue":"8","key":"2286_CR17","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.it.2023.06.002","volume":"44","author":"A de Baat","year":"2023","unstructured":"de Baat A, Trinh B, Ellingsgaard H, Donath MY. Physiological role of cytokines in the regulation of mammalian metabolism. Trends Immunol. 2023;44(8):613\u201327.","journal-title":"Trends Immunol"},{"issue":"3","key":"2286_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/ni.3659","volume":"18","author":"E Dror","year":"2017","unstructured":"Dror E, Dalmas E, Meier DT, et al. Postprandial macrophage-derived IL-1\u03b2 stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol. 2017;18(3):283\u201392.","journal-title":"Nat Immunol"},{"issue":"4","key":"2286_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2005317","volume":"16","author":"S Battu","year":"2018","unstructured":"Battu S, Afroz S, Giddaluru J, et al. Amino acid starvation sensing dampens IL-1\u03b2 production by activating riboclustering and autophagy. PLoS Biol. 2018;16(4):e2005317.","journal-title":"PLoS Biol"},{"issue":"10","key":"2286_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/nu15102294","volume":"15","author":"D Kounatidis","year":"2023","unstructured":"Kounatidis D, Vallianou N, Evangelopoulos A, et al. SGLT-2 inhibitors and the inflammasome: what\u2019s next in the 21st century? Nutrients. 2023;15(10):2294.","journal-title":"Nutrients"},{"issue":"5","key":"2286_CR21","doi-asserted-by":"publisher","first-page":"E745","DOI":"10.1152\/ajpendo.2001.280.5.E745","volume":"280","author":"PA Kern","year":"2001","unstructured":"Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5):E745\u201351.","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"17","key":"2286_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20176671","volume":"20","author":"E Sch\u00f6nberger","year":"2023","unstructured":"Sch\u00f6nberger E, Mihaljevi\u0107 V, Steiner K, et al. Immunomodulatory effects of SGLT2 inhibitors-targeting inflammation and oxidative stress in aging. Int J Environ Res Public Health. 2023;20(17):6671.","journal-title":"Int J Environ Res Public Health"},{"key":"2286_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04289-z","volume":"79","author":"R La Grotta","year":"2022","unstructured":"La Grotta R, de Candia P, Olivieri F, et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cell Mol Life Sci. 2022;79:273.","journal-title":"Cell Mol Life Sci"},{"key":"2286_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac544.2683","volume":"43","author":"P Theofilis","year":"2022","unstructured":"Theofilis P, Sagris M, Oikonomou E, et al. Anti-inflammatory potential of SGLT2 inhibitors: a systematic review and meta-analysis of preclinical studies in rodents. Eur Heart J. 2022;43:ehac544.2683.","journal-title":"Eur Heart J"},{"issue":"2","key":"2286_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.25122\/jml-2023-0343","volume":"17","author":"EM Shihab","year":"2024","unstructured":"Shihab EM, Kadhim HM, Shahooth SS. Dapagliflozin mitigates oxidative stress, inflammatory, and histopathological markers of aging in mice. J Med Life. 2024;17(2):157\u201363.","journal-title":"J Med Life"},{"key":"2286_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.768214","volume":"8","author":"YW Yu","year":"2021","unstructured":"Yu YW, Que JQ, Liu S, et al. Sodium\u2013glucose co-transporter-2 inhibitor of dapagliflozin attenuates myocardial ischemia\/reperfusion injury by limiting NLRP3 inflammasome activation and modulating autophagy. Front Cardiovasc Med. 2021;8:768214.","journal-title":"Front Cardiovasc Med."},{"key":"2286_CR27","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1122494","volume":"2022","author":"J Wang","year":"2022","unstructured":"Wang J, Huang X, Liu H, et al. Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function. Oxid Med Cell Longev. 2022;2022:1122494.","journal-title":"Oxid Med Cell Longev"},{"key":"2286_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109024","volume":"110","author":"Q Long","year":"2022","unstructured":"Long Q, Li L, Yang H, et al. SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis. Int Immunopharmacol. 2022;110:109024.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"2286_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.kint.2024.06.023","volume":"106","author":"YL Chou","year":"2024","unstructured":"Chou YL, Chen HL, Hsu BG, et al. Galectin-3 contributes to pathogenesis of IgA nephropathy. Kidney Int. 2024;106(4):658\u201370.","journal-title":"Kidney Int"},{"issue":"1","key":"2286_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05951-9","volume":"22","author":"Y Lai","year":"2024","unstructured":"Lai Y, Zhuang L, Zhu J, et al. Novel approach to alleviate lupus nephritis: targeting the NLRP3 inflammasome in CD8+CD69+CD103+\u00a0TRM\u00a0cells. J Transl Med. 2024;22(1):1139.","journal-title":"J Transl Med"},{"issue":"1","key":"2286_CR31","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202100909RR","volume":"36","author":"Q Ke","year":"2022","unstructured":"Ke Q, Shi C, Lv Y, et al. SGLT2 inhibitor counteracts NLRP3 inflammasome via tubular metabolite itaconate in fibrosis kidney. FASEB J. 2022;36(1):e22078.","journal-title":"FASEB J"},{"issue":"4","key":"2286_CR32","volume":"46","author":"PAB Machado J\u00fanior","year":"2024","unstructured":"Machado J\u00fanior PAB, Lass A, Pilger BI, Fornazari R, Moraes TP, Pinho RA. SGLT2 inhibitors and NLRP3 inflammasome: potential target in diabetic kidney disease. J Bras Nefrol. 2024;46(4):e20230187.","journal-title":"J Bras Nefrol"},{"issue":"3","key":"2286_CR33","doi-asserted-by":"publisher","first-page":"C1062","DOI":"10.1152\/ajpcell.00478.2024","volume":"328","author":"N Jantz-Naeem","year":"2025","unstructured":"Jantz-Naeem N, Guvencli N, B\u00f6ttcher-Loschinski R, B\u00f6ttcher M, Mougiakakos D, Kahlfuss S. Metabolic T-cell phenotypes: from bioenergetics to function. Am J Physiol Cell Physiol. 2025;328(3):C1062\u201375.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"3","key":"2286_CR34","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.cmet.2022.02.003","volume":"34","author":"SH M\u00f8ller","year":"2022","unstructured":"M\u00f8ller SH, Hsueh PC, Yu YR, Zhang L, Ho PC. Metabolic programs tailor T\u00a0cell immunity in viral infection, cancer, and aging. Cell Metab. 2022;34(3):378\u201395.","journal-title":"Cell Metab"},{"issue":"8","key":"2286_CR35","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41569-025-01130-5","volume":"22","author":"L Liberale","year":"2025","unstructured":"Liberale L, Tual-Chalot S, Sedej S, et al. Roadmap for alleviating the manifestations of ageing in the cardiovascular system. Nat Rev Cardiol. 2025;22(8):577\u2013605.","journal-title":"Nat Rev Cardiol"},{"issue":"6497","key":"2286_CR36","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1126\/science.aax0860","volume":"368","author":"G Desd\u00edn-Mic\u00f3","year":"2020","unstructured":"Desd\u00edn-Mic\u00f3 G, Soto-Heredero G, Aranda JF, et al. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science. 2020;368(6497):1371\u20136.","journal-title":"Science"},{"issue":"3","key":"2286_CR37","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1159\/000447827","volume":"39","author":"SK Bhavsar","year":"2016","unstructured":"Bhavsar SK, Singh Y, Sharma P, et al. Expression of JAK3 sensitive Na+ coupled glucose carrier SGLT1 in activated cytotoxic T lymphocytes. Cell Physiol Biochem. 2016;39(3):1209\u201328.","journal-title":"Cell Physiol Biochem"},{"key":"2286_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2024.112156","volume":"584","author":"D Wang","year":"2024","unstructured":"Wang D, Zhang Q, Dong W, et al. SGLT2 knockdown restores the Th17\/Treg balance and suppresses diabetic nephropathy in db\/db mice by regulating SGK1 via Na. Mol Cell Endocrinol. 2024;584:112156.","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"2286_CR39","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","volume":"35","author":"BJ Jenkins","year":"2023","unstructured":"Jenkins BJ, Blagih J, Ponce-Garcia FM, et al. Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity. Cell Metab. 2023;35(7):1132\u201346.","journal-title":"Cell Metab"},{"issue":"5","key":"2286_CR40","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/2211-5463.13147","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Zhang Z, Si Z, Yang Y, Li S, Xue Y. Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease. FEBS Open Bio. 2021;11(5):1395\u2013405.","journal-title":"FEBS Open Bio"},{"issue":"4","key":"2286_CR41","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/bjh.18293","volume":"198","author":"J Qin","year":"2022","unstructured":"Qin J, Liu Q, Liu A, et al. Empagliflozin modulates CD4+ T-cell differentiation via metabolic reprogramming in immune thrombocytopenia. Br J Haematol. 2022;198(4):765\u201375.","journal-title":"Br J Haematol"},{"issue":"8","key":"2286_CR42","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41581-023-00739-4","volume":"19","author":"M Wang","year":"2023","unstructured":"Wang M. Canagliflozin disrupts T cell activation. Nat Rev Nephrol. 2023;19(8):478.","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"2286_CR43","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1136\/ard-2023-224242","volume":"82","author":"XY Zhao","year":"2023","unstructured":"Zhao XY, Li SS, He YX, et al. SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis. 2023;82(10):1328\u201340.","journal-title":"Ann Rheum Dis"},{"issue":"10\u201311","key":"2286_CR44","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s00011-023-01796-y","volume":"72","author":"YJ Kim","year":"2023","unstructured":"Kim YJ, Jin J, Kim DH, et al. SGLT2 inhibitors prevent LPS-induced M1 macrophage polarization and alleviate inflammatory bowel disease by downregulating NHE1 expression. Inflamm Res. 2023;72(10\u201311):1981\u201397.","journal-title":"Inflamm Res"},{"issue":"4","key":"2286_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041670","volume":"26","author":"EY Rykova","year":"2025","unstructured":"Rykova EY, Klimontov VV, Shmakova E, Korbut AI, Merkulova TI, Kzhyshkowska J. Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages. Int J Mol Sci. 2025;26(4):1670.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2286_CR46","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002686","volume":"8","author":"H Wang","year":"2022","unstructured":"Wang H, Li T, Sun F, et al. Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I\/II trial. RMD Open. 2022;8(2):e002686.","journal-title":"RMD Open"},{"issue":"2","key":"2286_CR47","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ndt\/gfad175","volume":"39","author":"F Caravaca-Font\u00e1n","year":"2024","unstructured":"Caravaca-Font\u00e1n F, Stevens K, Padr\u00f3n M, et al. Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis. Nephrol Dial Transplant. 2024;39(2):328\u201340.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"2286_CR48","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1002\/art.43037","volume":"77","author":"KS Ma","year":"2025","unstructured":"Ma KS, Lo JE, Kyttaris VC, Tsokos GC, Costenbader KH. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors for the primary prevention of cardiovascular, renal events, and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: a population-based target trial emulation. Arthritis Rheumatol. 2025;77(4):414\u201322.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2286_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.16578","volume":"7","author":"FS Yen","year":"2024","unstructured":"Yen FS, Wang SI, Hsu CC, Hwu CM, Wei JC. Sodium-glucose cotransporter-2 inhibitors and nephritis among patients with systemic lupus erythematosus. JAMA Netw Open. 2024;7(6):e2416578.","journal-title":"JAMA Netw Open"},{"issue":"15","key":"2286_CR50","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98720","volume":"3","author":"P Cassis","year":"2018","unstructured":"Cassis P, Locatelli M, Cerullo D, et al. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. JCI Insight. 2018;3(15):e98720.","journal-title":"JCI Insight"},{"issue":"1","key":"2286_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01914-1","volume":"22","author":"X Li","year":"2024","unstructured":"Li X, Li Q, Jiang X, Song S, et al. Inhibition of SGLT2 protects podocytes in diabetic kidney disease by rebalancing mitochondria-associated endoplasmic reticulum membranes. Cell Commun Signal. 2024;22(1):534.","journal-title":"Cell Commun Signal"},{"key":"2286_CR52","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.83353","volume":"2","author":"M Ge","year":"2023","unstructured":"Ge M, Molina J, Kim JJ, et al. Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome. Elife. 2023;2:e83353.","journal-title":"Elife"},{"key":"2286_CR53","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1172\/JCI39492","volume":"120","author":"B Hartleben","year":"2010","unstructured":"Hartleben B, G\u00f6del M, Meyer-Schwesinger C, et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J Clin Investig. 2010;120:1084\u201396.","journal-title":"J Clin Investig"},{"key":"2286_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082987","volume":"21","author":"AI Korbut","year":"2020","unstructured":"Korbut AI, Taskaeva IS, Bgatova NP, et al. SGLT2 inhibitor empagliflozin and DPP4 inhibitor linagliptin reactivate glomerular autophagy in db\/db mice, a model of type 2 diabetes. Int J Mol Sci. 2020;21:2987.","journal-title":"Int J Mol Sci"},{"key":"2286_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110206","volume":"90","author":"L Yang","year":"2022","unstructured":"Yang L, Liang B, Li J, et al. Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK\/mTOR mediated autophagy pathway. Cell Signal. 2022;90:110206.","journal-title":"Cell Signal"},{"issue":"3","key":"2286_CR56","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/15548627.2024.2410621","volume":"21","author":"S Matsui","year":"2025","unstructured":"Matsui S, Yamamoto T, Takabatake Y, et al. Empagliflozin protects the kidney by reducing toxic ALB (albumin) exposure and preventing autophagic stagnation in proximal tubules. Autophagy. 2025;21(3):583\u201397.","journal-title":"Autophagy"},{"key":"2286_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/bs.pmbts.2020.03.005","volume":"172","author":"C Munz","year":"2020","unstructured":"Munz C. Autophagy in immunity. Prog Mol Biol Transl Sci. 2020;172:67\u201385.","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2286_CR58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.993869","volume":"13","author":"X Lv","year":"2022","unstructured":"Lv X, Wang J, Zhang L, et al. Canagliflozin reverses Th1\/Th2 imbalance and promotes podocyte autophagy in rats with membranous nephropathy. Front Immunol. 2022;13:993869.","journal-title":"Front Immunol"},{"key":"2286_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2014.00127","volume":"5","author":"S Merscher","year":"2014","unstructured":"Merscher S, Fornoni A. Podocyte pathology and nephropathy - sphingolipids in glomerular diseases. Front Endocrinol (Lausanne). 2014;5:127.","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"12","key":"2286_CR60","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s00424-024-03029-5","volume":"476","author":"S Schwalm","year":"2024","unstructured":"Schwalm S, Manaila R, Oftring A, Schaefer L, von Gunten S, Pfeilschifter J. The contribution of the sphingosine 1-phosphate signaling pathway to chronic kidney diseases: recent findings and new perspectives. Pflugers Arch. 2024;476(12):1845\u201361.","journal-title":"Pflugers Arch"},{"issue":"4","key":"2286_CR61","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ekir.2023.01.031","volume":"8","author":"Y Drexler","year":"2023","unstructured":"Drexler Y, Molina J, Elfassy T, et al. Identification of glomerular and plasma apolipoprotein m as novel biomarkers in glomerular disease. Kidney Int Rep. 2023;8(4):884\u201397.","journal-title":"Kidney Int Rep"},{"issue":"6 Pt 2","key":"2286_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101839","volume":"4","author":"C Valenzuela Ripoll","year":"2025","unstructured":"Valenzuela Ripoll C, Lotfinaghsh A, Guo Z, et al. Sodium-glucose cotransporter inhibition preserves apolipoprotein M during acute inflammation in mice and humans. JACC Adv. 2025;4(6 Pt 2):101839.","journal-title":"JACC Adv."},{"key":"2286_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052883","volume":"23","author":"R P\u00e9rez-Villavicencio","year":"2022","unstructured":"P\u00e9rez-Villavicencio R, Flores-Estrada J, Franco M, et al. Effect of empagliflozin on sphingolipid catabolism in diabetic and hypertensive rats. Int J Mol Sci. 2022;23:2883.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2286_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/apha.14108","volume":"240","author":"LAK van der Pluijm","year":"2024","unstructured":"van der Pluijm LAK, Koudijs A, Stam W, et al. SGLT2 inhibition promotes glomerular repopulation by cells of renin lineage in experimental kidney disease. Acta Physiol (Oxf). 2024;240(3):e14108.","journal-title":"Acta Physiol (Oxf)"},{"issue":"6","key":"2286_CR65","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/ndt\/gfae019","volume":"39","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Del Vecchio L. Cardio-renoprotective effects of SGLT2 inhibitors: the role of anaemia correction. Nephrol Dial Transplant. 2024;39(6):904\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2286_CR66","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1002\/ehf2.13615","volume":"8","author":"D Fitchett","year":"2021","unstructured":"Fitchett D, Inzucchi SE, Zinman B, et al. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Heart Fail. 2021;8(6):4517\u201327.","journal-title":"ESC Heart Fail."},{"issue":"9","key":"2286_CR67","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1093\/ndt\/gfae032","volume":"39","author":"C Wanner","year":"2024","unstructured":"Wanner C, Nangaku M, Kraus BJ, et al. How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial. Nephrol Dial Transplant. 2024;39(9):1504\u201313.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2286_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-51343-1","volume":"9","author":"R Bessho","year":"2019","unstructured":"Bessho R, Takiyama Y, Takiyama T, et al. Hypoxia-inducible factor-1\u03b1 is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy. Sci Rep. 2019;9(1):14754.","journal-title":"Sci Rep"},{"issue":"1","key":"2286_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01257-8","volume":"7","author":"QJ Wu","year":"2022","unstructured":"Wu QJ, Zhang TN, Chen HH, et al. The sirtuin family in health and disease. Signal Transduct Target Ther. 2022;7(1):402.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2286_CR70","doi-asserted-by":"publisher","DOI":"10.3390\/life14010020","volume":"14","author":"M Minisini","year":"2023","unstructured":"Minisini M, Cricchi E, Brancolini C. Acetylation and phosphorylation in the regulation of hypoxia-inducible factor activities: additional options to modulate adaptations to changes in oxygen levels. Life. 2023;14(1):20.","journal-title":"Life"},{"issue":"538","key":"2286_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay1620","volume":"12","author":"PM Chen","year":"2020","unstructured":"Chen PM, Wilson PC, Shyer JA, et al. Kidney tissue hypoxia dictates T cell-mediated injury in murine lupus nephritis. Sci Transl Med. 2020;12(538):eaay1620.","journal-title":"Sci Transl Med"},{"issue":"2","key":"2286_CR72","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s13105-021-00788-y","volume":"77","author":"AK Singh","year":"2021","unstructured":"Singh AK, Kolligundla LP, Francis J, Pasupulati AK. Detrimental effects of hypoxia on glomerular podocytes. J Physiol Biochem. 2021;77(2):193\u2013203.","journal-title":"J Physiol Biochem"},{"issue":"26","key":"2286_CR73","doi-asserted-by":"publisher","first-page":"15160","DOI":"10.1073\/pnas.2000943117","volume":"117","author":"C Jing","year":"2020","unstructured":"Jing C, Castro-Dopico T, Richoz N, et al. Macrophage metabolic reprogramming presents a therapeutic target in lupus nephritis. Proc Natl Acad Sci USA. 2020;117(26):15160\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2286_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109020","volume":"27","author":"A Tomita-Yagi","year":"2024","unstructured":"Tomita-Yagi A, Ozeki-Okuno N, Watanabe-Uehara N, et al. The importance of proinflammatory failed-repair tubular epithelia as a predictor of diabetic kidney disease progression. iScience. 2024;27(2):109020.","journal-title":"iScience"},{"key":"2286_CR75","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00125-023-05876-w","volume":"66","author":"S Gullaksen","year":"2023","unstructured":"Gullaksen S, Vernstr\u00f8m L, S\u00f8rensen SS, et al. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial. Diabetologia. 2023;66:813\u201325.","journal-title":"Diabetologia"},{"key":"2286_CR76","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","volume":"94","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Nakano D, Guan Y, et al. A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice. Kidney Int. 2018;94:524\u201335.","journal-title":"Kidney Int"},{"issue":"5","key":"2286_CR77","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41581-023-00694-0","volume":"19","author":"AB Sanz","year":"2023","unstructured":"Sanz AB, Sanchez-Ni\u00f1o MD, Ramos AM, Ortiz A. Regulated cell death pathways in kidney disease. Nat Rev Nephrol. 2023;19(5):281\u201399.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"2286_CR78","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/path.5882","volume":"257","author":"L Mart\u00edn-Saiz","year":"2022","unstructured":"Mart\u00edn-Saiz L, Guerrero-Mauvecin J, Mart\u00edn-Sanchez D, et al. Ferrostatin-1 modulates dysregulated kidney lipids in acute kidney injury. J Pathol. 2022;257(3):285\u201399.","journal-title":"J Pathol"},{"issue":"1","key":"2286_CR79","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1681\/ASN.2015121376","volume":"28","author":"D Martin-Sanchez","year":"2017","unstructured":"Martin-Sanchez D, Ruiz-Andres O, Poveda J, et al. Ferroptosis, but not necroptosis, is important in nephrotoxic folic acid-induced AKI. J Am Soc Nephrol. 2017;28(1):218\u201329.","journal-title":"J Am Soc Nephrol"},{"key":"2286_CR80","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2022.12.088","volume":"195","author":"Q Lu","year":"2023","unstructured":"Lu Q, Yang L, Xiao JJ, et al. Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK\/NRF2 pathway. Free Radic Biol Med. 2023;195:89\u2013102.","journal-title":"Free Radic Biol Med"},{"issue":"7-9","key":"2286_CR81","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1089\/ars.2022.0169","volume":"40","author":"YH Wang","year":"2024","unstructured":"Wang YH, Chang DY, Zhao MH, Chen M. Dapagliflozin alleviates diabetic kidney disease via hypoxia inducible factor 1\u03b1\/heme oxygenase 1-mediated ferroptosis. Antioxid Redox Signal. 2024;40(7\u20139):492\u2013509.","journal-title":"Antioxid Redox Signal"},{"key":"2286_CR82","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9735555","volume":"2022","author":"B Huang","year":"2022","unstructured":"Huang B, Wen W, Ye S. Dapagliflozin ameliorates renal tubular ferroptosis in diabetes via SLC40A1 stabilization. Oxid Med Cell Longev. 2022;2022:9735555.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"2286_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71416-0","volume":"14","author":"Y Hirashima","year":"2024","unstructured":"Hirashima Y, Nakano T, Torisu K, Aihara S, Wakisaka M, Kitazono T. SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis. Sci Rep. 2024;14(1):20386.","journal-title":"Sci Rep"},{"issue":"7","key":"2286_CR84","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/1061186X.2024.2353363","volume":"32","author":"SQ Yang","year":"2024","unstructured":"Yang SQ, Zhao X, Zhang J, Liao DY, Wang YH, Wang YG. Ferroptosis in renal fibrosis: a mini-review. J Drug Target. 2024;32(7):785\u201393.","journal-title":"J Drug Target"},{"key":"2286_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2024.149009","volume":"934","author":"G Xiao","year":"2025","unstructured":"Xiao G, Tang S, Zhang Y, Yuan Q, Sun D, Wang W. Downregulation of ferroptosis-related ATF3 alleviates lupus nephritis progression. Gene. 2025;934:149009.","journal-title":"Gene"},{"issue":"2","key":"2286_CR86","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1152\/physrev.00041.2016","volume":"98","author":"M Sarhan","year":"2018","unstructured":"Sarhan M, Land WG, Tonnus W, Hugo CP, Linkermann A. Origin and consequences of necroinflammation. Physiol Rev. 2018;98(2):727\u201380.","journal-title":"Physiol Rev"},{"issue":"14","key":"2286_CR87","doi-asserted-by":"publisher","first-page":"5438","DOI":"10.7150\/ijbs.74675","volume":"18","author":"J Wu","year":"2022","unstructured":"Wu J, Shao X, Shen J, et al. Downregulation of PPAR\u03b1 mediates FABP1 expression, contributing to IgA nephropathy by stimulating ferroptosis in human mesangial cells. Int J Biol Sci. 2022;18(14):5438\u201358.","journal-title":"Int J Biol Sci"},{"issue":"12","key":"2286_CR88","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13121540","volume":"13","author":"W Xu","year":"2024","unstructured":"Xu W, Zhu Y, Wang S, Liu J, Li H. From adipose to ailing kidneys: the role of lipid metabolism in obesity-related chronic kidney disease. Antioxidants (Basel). 2024;13(12):1540.","journal-title":"Antioxidants (Basel)"},{"issue":"4","key":"2286_CR89","doi-asserted-by":"publisher","first-page":"755","DOI":"10.34067\/KID.0006152020","volume":"2","author":"JJ Kim","year":"2021","unstructured":"Kim JJ, Wilbon SS, Fornoni A. Podocyte lipotoxicity in CKD. Kidney360. 2021;2(4):755\u201362.","journal-title":"Kidney360"},{"key":"2286_CR90","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00125-008-1127-4","volume":"51","author":"E Santini","year":"2008","unstructured":"Santini E, Lupi R, Baldi S, et al. Effects of different LDL particles on inflammatory molecules in human mesangial cells. Diabetologia. 2008;51:2117\u201325.","journal-title":"Diabetologia"},{"key":"2286_CR91","doi-asserted-by":"crossref","unstructured":"Nakhoul N, Batuman V. Role of proximal tubules in the pathogenesis of kidney disease. In: Experimental models for renal diseases, vol. 169. Basel: Karger Publishers, editor Guillermo A. Herrera; 2011. p. 37\u201350.","DOI":"10.1159\/000313944"},{"issue":"1","key":"2286_CR92","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010137","volume":"19","author":"D Wang","year":"2018","unstructured":"Wang D, Luo Y, Wang X, et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in Western diet induced obesity mice. Int J Mol Sci. 2018;19(1):137.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2286_CR93","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-024-01271-6","volume":"16","author":"J Sun","year":"2024","unstructured":"Sun J, Zhang X, Wang S, et al. Dapagliflozin improves podocytes injury in diabetic nephropathy via regulating cholesterol balance through KLF5 targeting the ABCA1 signalling pathway. Diabetol Metab Syndr. 2024;16(1):38.","journal-title":"Diabetol Metab Syndr"},{"issue":"9","key":"2286_CR94","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1172\/JCI85939","volume":"126","author":"CE Pedigo","year":"2016","unstructured":"Pedigo CE, Ducasa GM, Leclercq F, et al. Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury. J Clin Investig. 2016;126(9):3336\u201350.","journal-title":"J Clin Investig"},{"issue":"1","key":"2286_CR95","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1038\/s41467-021-24890-3","volume":"12","author":"MB Wright","year":"2021","unstructured":"Wright MB, Varona Santos J, Kemmer C, et al. Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease. Nat Commun. 2021;12(1):4662.","journal-title":"Nat Commun"},{"issue":"22","key":"2286_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212408","volume":"22","author":"CC Huang","year":"2021","unstructured":"Huang CC, Chou CA, Chen WY, et al. Empagliflozin ameliorates free fatty acid induced-lipotoxicity in renal proximal tubular cells via the PPAR\u03b3\/CD36 pathway in obese mice. Int J Mol Sci. 2021;22(22):12408.","journal-title":"Int J Mol Sci"},{"key":"2286_CR97","doi-asserted-by":"crossref","unstructured":"Shi Y, Bhalla V. Kidney single-cell transcriptomes uncover SGLT2i-induced metabolic reprogramming via restoring glycolysis and fatty acid oxidation. BioRxiv. (Preprint). 2023.","DOI":"10.1101\/2023.10.31.564836"},{"key":"2286_CR98","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2020.00013","volume":"7","author":"B Cuenoud","year":"2020","unstructured":"Cuenoud B, Hartweg M, Godin JP, et al. Metabolism of exogenous d-beta-hydroxybutyrate, an energy substrate avidly consumed by the heart and kidney. Front Nutr. 2020;7:13.","journal-title":"Front Nutr"},{"issue":"7","key":"2286_CR99","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care. 2016;39(7):1108\u201314.","journal-title":"Diabetes Care"},{"issue":"3","key":"2286_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100176","volume":"63","author":"K Wallenius","year":"2022","unstructured":"Wallenius K, Kroon T, Hagstedt T, et al. The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis. J Lipid Res. 2022;63(3):100176.","journal-title":"J Lipid Res"},{"issue":"1","key":"2286_CR101","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02185-0","volume":"19","author":"H Kolb","year":"2021","unstructured":"Kolb H, Kempf K, R\u00f6hling M, Lenzen-Schulte M, Schloot NC, Martin S. Ketone bodies: from enemy to friend and guardian angel. BMC Med. 2021;19(1):313.","journal-title":"BMC Med"},{"key":"2286_CR102","first-page":"2024","volume":"21","author":"J Mandal","year":"2024","unstructured":"Mandal J, Aryal S, Manandhar I, et al. The ketone body \u03b2-hydroxybutyrate mediated epigenetic chromatin \u03b2-hydroxybutyrylation protects kidneys. BioRxiv (Preprint). 2024;21:2024.","journal-title":"BioRxiv (Preprint)."},{"issue":"7","key":"2286_CR103","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1134\/S0006297924070149","volume":"89","author":"VV Nesterova","year":"2024","unstructured":"Nesterova VV, Babenkova PI, Brezgunova AA, et al. Differences in the effect of beta-hydroxybutyrate on the mitochondrial biogenesis. Oxidative stress and inflammation markers in tissues from young and old rats. Biochemistry (Mosc). 2024;89(7):1336\u201348.","journal-title":"Biochemistry (Mosc)"},{"issue":"4","key":"2286_CR104","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.18632\/aging.101838","volume":"11","author":"DH Kim","year":"2019","unstructured":"Kim DH, Park MH, Ha S, et al. Anti-inflammatory action of \u03b2-hydroxybutyrate via modulation of PGC-1\u03b1 and FoxO1, mimicking calorie restriction. Aging (Albany NY). 2019;11(4):1283\u2013304.","journal-title":"Aging (Albany NY)."},{"issue":"3","key":"2286_CR105","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cmet.2020.06.020","volume":"32","author":"I Tomita","year":"2020","unstructured":"Tomita I, Kume S, Sugahara S, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. 2020;32(3):404\u201319.","journal-title":"Cell Metab"},{"issue":"12","key":"2286_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-07268-3","volume":"15","author":"YP Bai","year":"2024","unstructured":"Bai YP, Xing YJ, Ma T, et al. \u03b2-Hydroxybutyrate suppresses M1 macrophage polarization through \u03b2-hydroxybutyrylation of the STAT1 protein. Cell Death Dis. 2024;15(12):874.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2286_CR107","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41556-019-0440-0","volume":"22","author":"H Zhang","year":"2020","unstructured":"Zhang H, Tang K, Ma J, et al. Ketogenesis-generated \u03b2-hydroxybutyrate is an epigenetic regulator of CD8+ T-cell memory development. Nat Cell Biol. 2020;22(1):18\u201325.","journal-title":"Nat Cell Biol"},{"issue":"7928","key":"2286_CR108","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41586-022-05128-8","volume":"609","author":"F Karagiannis","year":"2022","unstructured":"Karagiannis F, Peukert K, Surace L, et al. Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19. Nature. 2022;609(7928):801\u20137.","journal-title":"Nature"},{"key":"2286_CR109","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev-physiol-042222-024724","volume":"86","author":"M Chrysopoulou","year":"2024","unstructured":"Chrysopoulou M, Rinschen MM. Metabolic rewiring and communication: an integrative view of kidney proximal tubule function. Annu Rev Physiol. 2024;86:405\u20137.","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"2286_CR110","first-page":"4","volume":"8","author":"HM Kang","year":"2022","unstructured":"Kang HM, Ahn SH, Choi P, et al. Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells. Cell Death Discov. 2022;8(1):4.","journal-title":"Cell Death Discov."},{"issue":"5","key":"2286_CR111","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.trsl.2010.11.006","volume":"157","author":"BL Tang","year":"2011","unstructured":"Tang BL. Sirt1\u2019s systemic protective roles and its promise as a target in antiaging medicine. Transl Res. 2011;157(5):276\u201384.","journal-title":"Transl Res"},{"key":"2286_CR112","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejphar.2018.05.017","volume":"832","author":"K Huang","year":"2018","unstructured":"Huang K, Li R, Wei W. Sirt1 activation prevents anti-Thy 1.1 mesangial proliferative glomerulonephritis in the rat through the Nrf2\/ARE pathway. Eur J Pharmacol. 2018;832:138\u201344.","journal-title":"Eur J Pharmacol"},{"key":"2286_CR113","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1681\/ASN.2014030289","volume":"26","author":"S Motonishi","year":"2015","unstructured":"Motonishi S, Nangaku M, Wada T, et al. Sirtuin1 maintains actin cytoskeleton by deacetylation of cortactin in injured podocytes. J Am Soc Nephrol. 2015;26:939\u201359.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"2286_CR114","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1042\/CS20171410","volume":"132","author":"D Olivares","year":"2018","unstructured":"Olivares D, Perez-Hernandez J, Forner MJ, et al. Urinary levels of sirtuin-1 associated with disease activity in lupus nephritis. Clin Sci (Lond). 2018;132(5):569\u201379.","journal-title":"Clin Sci (Lond)"},{"key":"2286_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116284","volume":"309","author":"LY He","year":"2023","unstructured":"He LY, Niu SQ, Yang CX, et al. Cordyceps proteins alleviate lupus nephritis through modulation of the STAT3\/mTOR\/NF-\u043aB signaling pathway. J Ethnopharmacol. 2023;309:116284.","journal-title":"J Ethnopharmacol"},{"issue":"8","key":"2286_CR116","first-page":"1220","volume":"49","author":"Y Liu","year":"2024","unstructured":"Liu Y, Leng B, Xia M, et al. Regulatory role of the mTOR signaling pathway in autophagy and mesangial proliferation in IgA nephropathy. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024;49(8):1220\u201331.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"2286_CR117","doi-asserted-by":"publisher","first-page":"6424","DOI":"10.1002\/jcp.30316","volume":"236","author":"K Jaikumkao","year":"2021","unstructured":"Jaikumkao K, Promsan S, Thongnak L. Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK\/mTOR signaling pathway in obese rats. J Cell Physiol. 2021;236:6424\u201340.","journal-title":"J Cell Physiol"},{"issue":"16","key":"2286_CR118","doi-asserted-by":"publisher","first-page":"8676","DOI":"10.3390\/ijms25168676","volume":"25","author":"D Troise","year":"2024","unstructured":"Troise D, Mercuri S, Infante B, et al. mTOR and SGLT-2 inhibitors: their synergistic effect on age-related processes. Int J Mol Sci. 2024;25(16):8676.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2286_CR119","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/ndt\/gfaf068","volume":"40","author":"A Ortiz","year":"2025","unstructured":"Ortiz A, Kramer A, Rychl\u00edk I, et al. Maintaining kidney health in aging societies: a JSN and ERA call to action. Nephrol Dial Transplant. 2025;40(8):1498\u2013511.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2286_CR120","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1681\/ASN.2013030294","volume":"24","author":"MD Sanchez-Ni\u00f1o","year":"2013","unstructured":"Sanchez-Ni\u00f1o MD, Sanz AB, Ortiz A. Klotho to treat kidney fibrosis. J Am Soc Nephrol. 2013;24(5):687\u20139.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2286_CR121","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.cell.2025.03.011","volume":"188","author":"G Kroemer","year":"2025","unstructured":"Kroemer G, Maier AB, Cuervo AM, et al. From geroscience to precision geromedicine: understanding and managing aging. Cell. 2025;188(8):2043\u201362.","journal-title":"Cell"},{"issue":"10","key":"2286_CR122","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1093\/ndt\/gfx376","volume":"33","author":"B Fernandez-Fernandez","year":"2018","unstructured":"Fernandez-Fernandez B, Izquierdo MC, Vali\u00f1o-Rivas L, et al. Albumin downregulates Klotho in tubular cells. Nephrol Dial Transplant. 2018;33(10):1712\u201322.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2286_CR123","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1681\/ASN.2014010104","volume":"26","author":"S de Seigneux","year":"2015","unstructured":"de Seigneux S, Courbebaisse M, Rutkowski JM, et al. Proteinuria increases plasma phosphate by altering its tubular handling. J Am Soc Nephrol. 2015;26(7):1608\u201318.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"2286_CR124","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1073\/pnas.0611079104","volume":"104","author":"Y Haruna","year":"2007","unstructured":"Haruna Y, Kashihara N, Satoh M, et al. Amelioration of progressive renal injury by genetic manipulation of Klotho gene. Proc Natl Acad Sci USA. 2007;104(7):2331\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"2286_CR125","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/HJH.0000000000002845","volume":"39","author":"T Takenaka","year":"2021","unstructured":"Takenaka T, Hasan A, Marumo T, et al. Klotho supplementation attenuates blood pressure and albuminuria in murine model of IgA nephropathy. J Hypertens. 2021;39(8):1567\u201376.","journal-title":"J Hypertens"},{"issue":"1","key":"2286_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-04563-1","volume":"6","author":"E Charrin","year":"2023","unstructured":"Charrin E, Dabaghie D, Sen I, et al. Soluble Klotho protects against glomerular injury through regulation of ER stress response. Commun Biol. 2023;6(1):208.","journal-title":"Commun Biol"},{"key":"2286_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.177229","volume":"988","author":"T Takenaka","year":"2025","unstructured":"Takenaka T, Kobori H, Kurosaki Y, et al. Klotho supplementation decreases blood pressure and albuminuria in mice with lupus nephritis. Eur J Pharmacol. 2025;988:177229.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2286_CR128","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1681\/ASN.2015080888","volume":"28","author":"JH Kim","year":"2017","unstructured":"Kim JH, Xie J, Hwang KH, et al. Klotho may ameliorate proteinuria by targeting TRPC6 channels in podocytes. J Am Soc Nephrol. 2017;28(1):140\u201351.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2286_CR129","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.kint.2022.04.028","volume":"102","author":"X Chen","year":"2022","unstructured":"Chen X, Tan H, Xu J, et al. Klotho-derived peptide 6 ameliorates diabetic kidney disease by targeting Wnt\/\u03b2-catenin signaling. Kidney Int. 2022;102(3):506\u201320.","journal-title":"Kidney Int"},{"issue":"2","key":"2286_CR130","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1681\/ASN.0000000501","volume":"36","author":"B Wooden","year":"2025","unstructured":"Wooden B, Beenken A, Martinelli E, et al. Natural history and clinicopathological associations of TRPC6-associated podocytopathy. J Am Soc Nephrol. 2025;36(2):274\u201389.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"2286_CR131","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1016\/j.ekir.2023.09.026","volume":"8","author":"H Trachtman","year":"2023","unstructured":"Trachtman H, Kretzler M, Desmond HE, Choi W, Manuel RC, Soleymanlou N. TRPC6 inhibitor BI 764198 in focal segmental glomerulosclerosis: phase 2 study design. Kidney Int Rep. 2023;8(12):2822\u20135.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"2286_CR132","doi-asserted-by":"publisher","first-page":"F1329","DOI":"10.1152\/ajprenal.00487.2016","volume":"311","author":"O Ruiz-Andres","year":"2016","unstructured":"Ruiz-Andres O, Sanchez-Ni\u00f1o MD, Moreno JA, et al. Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms. Am J Physiol Renal Physiol. 2016;311(6):F1329\u201340.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2286_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113677","volume":"154","author":"C Mora-Fern\u00e1ndez","year":"2022","unstructured":"Mora-Fern\u00e1ndez C, S\u00e1nchez-Ni\u00f1o MD, Donate-Correa J, et al. Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: a clinical and experimental study. Biomed Pharmacother. 2022;154:113677.","journal-title":"Biomed Pharmacother"},{"key":"2286_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1242108","volume":"10","author":"C Mora-Fern\u00e1ndez","year":"2023","unstructured":"Mora-Fern\u00e1ndez C, P\u00e9rez A, Mollar A, DAPA-VO Investigators, et al. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction: a substudy of the DAPA-VO2\u00a0study. Front Cardiovasc Med. 2023;10:1242108.","journal-title":"Front Cardiovasc Med"},{"key":"2286_CR135","doi-asserted-by":"crossref","unstructured":"Geng L, Ping J, Wu R, et al. Systematic profiling reveals betaine as an exercise mimetic for geroprotection. Cell. 2025;188(19):5403\u20135425.","DOI":"10.1016\/j.cell.2025.06.001"},{"issue":"7","key":"2286_CR136","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.164296","volume":"8","author":"A Kogot-Levin","year":"2023","unstructured":"Kogot-Levin A, Riahi Y, Abramovich I, et al. Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition. JCI Insight. 2023;8(7):e164296.","journal-title":"JCI Insight"},{"issue":"2","key":"2286_CR137","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"15","key":"2286_CR138","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, DAPA-CKD Trial Committees and Investigators, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"1","key":"2286_CR139","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41591-024-03330-x","volume":"31","author":"MA Anderegg","year":"2025","unstructured":"Anderegg MA, Schietzel S, Bargagli M, et al. Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trial. Nat Med. 2025;31(1):286\u201393.","journal-title":"Nat Med"},{"issue":"7","key":"2286_CR140","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.70275","volume":"13","author":"Y Lytvyn","year":"2025","unstructured":"Lytvyn Y, Scholtes RA, Boorsma EM, et al. Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure. Physiol Rep. 2025;13(7):e70275.","journal-title":"Physiol Rep"},{"issue":"10","key":"2286_CR141","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1111\/dom.14779","volume":"24","author":"T Sen","year":"2022","unstructured":"Sen T, Koshino A, Neal B, et al. Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: a post hoc mediation analysis of the CANVAS trial. Diabetes Obes Metab. 2022;24(10):1950\u20136.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2286_CR142","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Hartmann E, Freyberger A, et al. Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol. 2021;52(8):642\u201352.","journal-title":"Am J Nephrol"},{"issue":"4","key":"2286_CR143","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jphs.2025.09.008","volume":"159","author":"J Horizono","year":"2025","unstructured":"Horizono J, Mizumoto K, Suico MA, et al. Dapagliflozin with losartan but not olmesartan has an add-on protective effect in experimental Alport syndrome. J Pharmacol Sci. 2025;159(4):252\u20135.","journal-title":"J Pharmacol Sci"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02286-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02286-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02286-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:01:57Z","timestamp":1774072917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02286-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":143,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2286"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02286-1","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]},"assertion":[{"value":"28 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lucia Del Vecchio is an Editorial Board member of\n                      Drugs\n                      . Lucia Del Vecchio was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Lucia Del Vecchio has received speaker fees at meetings with indirect support of AstraZeneca, Boheringer Ingelheim, Bayer, Vifor, Astellas, and Amgen. Beatriz Fernandez-Fernandez has received grants from Esteve and AstraZeneca; consultancy or speaker fees or travel support from AstraZeneca, Bayer, Menarini, Novo-Nordisk, Boehringer Ingelheim, Mundipharma, Lilly, and Amgen; and participated in data safety monitoring boards or advisory boards for Astrazeneca, Bayer, Novo-Nordisk, Boehringer Ingelheim, Mundipharma, Lilly, and Amgen. Alessia Fornoni is an inventor on pending or issued patents (US10,183,038, US10,052,345, US11,344,604) aimed to diagnose or treat proteinuric renal diseases. She stands to gain royalties from their future commercialization. Alessia Fornoni is the Vice-President of L&F Health LLC, holds equity interests in L&F Research, and is the inventor of assets developed by ZyVersa Therapeutics. ZyVersa Therapeutics has licensed worldwide rights to develop and commercialize hydroxypropyl-beta-cyclodextrin for the treatment of kidney disease from L&F Research. Alessia Fornoni holds equities in River 3 Renal Corporation. In the previous 12 months, Alessia Fornoni has received consulting fees from Travere, Alexion, Novartis, Vera Therapeutics, Bayer, and Aion. Andreas Kronbichler has received consultancy of speaker fees or travel support from Amgen, Argenx, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Delta4, GlaxoSmithKline, Miltenyi Biotec, Novartis, Novo Nordisk, Otsuka, Roche, Sobi, and Walden Biosciences. Alberto Ortiz has received consultancy or speaker fees or travel support from Astellas, Astrazeneca, Bioporto, Boehringer Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Sobi, Menarini, Lilly, Chiesi, Otsuka, Novo-Nordisk, Sysmex, Vifor Fresenius Medical Care Renal Pharma, and Spafarma; and is a Director of the Catedra UAM-AstraZeneca of CKD and electrolytes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LDV conceived and coordinated the article. All authors wrote sections and reviewed and approved the final version of the article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}